ATE363483T1 - Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen - Google Patents
Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignenInfo
- Publication number
- ATE363483T1 ATE363483T1 AT04779540T AT04779540T ATE363483T1 AT E363483 T1 ATE363483 T1 AT E363483T1 AT 04779540 T AT04779540 T AT 04779540T AT 04779540 T AT04779540 T AT 04779540T AT E363483 T1 ATE363483 T1 AT E363483T1
- Authority
- AT
- Austria
- Prior art keywords
- disorder
- metabolite
- inhibitor
- symptom
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49221803P | 2003-07-31 | 2003-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE363483T1 true ATE363483T1 (de) | 2007-06-15 |
Family
ID=34115611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04779540T ATE363483T1 (de) | 2003-07-31 | 2004-07-29 | Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen |
Country Status (11)
Country | Link |
---|---|
US (1) | US7312223B2 (de) |
EP (1) | EP1648895B1 (de) |
JP (1) | JP2007500714A (de) |
CN (1) | CN1860119A (de) |
AT (1) | ATE363483T1 (de) |
CA (1) | CA2533715A1 (de) |
DE (1) | DE602004006756T2 (de) |
ES (1) | ES2284056T3 (de) |
HK (1) | HK1082739A1 (de) |
MX (1) | MXPA06001195A (de) |
WO (1) | WO2005012303A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
DE60307628T2 (de) * | 2002-05-31 | 2007-08-09 | Schering Corporation | Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen |
AU2005277384B2 (en) * | 2004-08-17 | 2011-11-17 | The Johns Hopkins University | PDE5 inhibitor compositions and methods for treating cardiac indications |
KR20090087795A (ko) * | 2008-02-13 | 2009-08-18 | 한양대학교 산학협력단 | 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트 |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
US20100261737A1 (en) * | 2009-04-10 | 2010-10-14 | Medtronic Vascular, Inc. | Method of Treating Erectile Dysfunction |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
CN106770618A (zh) * | 2015-11-20 | 2017-05-31 | 中国康复研究中心 | 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
IL98559A0 (en) * | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
GB9020959D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
CA2098846A1 (en) * | 1990-12-21 | 1992-06-22 | David G. Smith | Xanthine derivatives |
GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
WO1994019351A1 (en) * | 1993-02-26 | 1994-09-01 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
DE60307628T2 (de) | 2002-05-31 | 2007-08-09 | Schering Corporation | Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen |
TW200404802A (en) | 2002-05-31 | 2004-04-01 | Schering Corp | Xanthine phosphodiesterase V inhibitor polymorphs |
-
2004
- 2004-07-29 MX MXPA06001195A patent/MXPA06001195A/es active IP Right Grant
- 2004-07-29 DE DE602004006756T patent/DE602004006756T2/de not_active Expired - Fee Related
- 2004-07-29 CN CNA2004800280878A patent/CN1860119A/zh active Pending
- 2004-07-29 ES ES04779540T patent/ES2284056T3/es not_active Expired - Lifetime
- 2004-07-29 WO PCT/US2004/024525 patent/WO2005012303A1/en active IP Right Grant
- 2004-07-29 US US10/901,574 patent/US7312223B2/en not_active Expired - Fee Related
- 2004-07-29 EP EP04779540A patent/EP1648895B1/de not_active Expired - Lifetime
- 2004-07-29 AT AT04779540T patent/ATE363483T1/de not_active IP Right Cessation
- 2004-07-29 JP JP2006522068A patent/JP2007500714A/ja active Pending
- 2004-07-29 CA CA002533715A patent/CA2533715A1/en not_active Abandoned
-
2006
- 2006-05-03 HK HK06105215A patent/HK1082739A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1082739A1 (en) | 2006-06-16 |
EP1648895A1 (de) | 2006-04-26 |
MXPA06001195A (es) | 2006-04-11 |
ES2284056T3 (es) | 2007-11-01 |
US7312223B2 (en) | 2007-12-25 |
DE602004006756T2 (de) | 2008-01-24 |
JP2007500714A (ja) | 2007-01-18 |
CN1860119A (zh) | 2006-11-08 |
WO2005012303A1 (en) | 2005-02-10 |
CA2533715A1 (en) | 2005-02-10 |
US20050026939A1 (en) | 2005-02-03 |
DE602004006756D1 (de) | 2007-07-12 |
EP1648895B1 (de) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1082739A1 (en) | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction | |
ATE554765T1 (de) | Imidazoä1,2-aüpyridine und ihre verwendung als arzneimittel | |
Trinity et al. | Passive leg movement and nitric oxide-mediated vascular function: the impact of age | |
WO2005123718A3 (en) | Benzimidazolone carboxylic acid derivatives | |
BRPI0513444A (pt) | antagonistas do receptor da histamina 3 | |
JP2013056911A (ja) | 運動障害の予防および/または治療剤 | |
JP2007537293A5 (de) | ||
CN108697807A (zh) | 代谢功能障碍引起的肿瘤的治疗 | |
DE60238929D1 (de) | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind | |
CN100999517A (zh) | 吡唑甲酰胺衍生物,药物组合物和其制备方法 | |
NZ597222A (en) | Substituted 8-[6-Amino-3-Pyridyl]Xanthines | |
JP7137650B2 (ja) | テトラヒドロイソキノリン誘導体 | |
JP2007500714A5 (de) | ||
CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
JPH0273015A (ja) | 置換3,4‐ジヒドロ‐2h‐ベンゾピラン類の肺の閉鎖性機能障害および/または輸出尿路の障害の治療薬としての使用 | |
EP2094285B1 (de) | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) | |
Akbarinia et al. | Effects of different types of isokinetic contraction on hemodynamic parameters in men. | |
ATE496621T1 (de) | Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika | |
CN107998140B (zh) | 化合物r1的用途 | |
Boss | 20 Years of Medicinal Chemistry–Always Look at the Bright Side (of Life) | |
RU2010148433A (ru) | Производные бензоциклогептана и бензоксепина | |
CN106986878A (zh) | 一种预防和治疗荨麻疹的药物及其制备方法 | |
Mishra et al. | Auditory, visual and postural reaction time among middle aged type 2 diabetics and healthy individuals–a cross-sectional study | |
Khabibulina et al. | Impact of metabolic therapy on the state of cerebral hemodynamics in hypoestrogenemia | |
Bofosa et al. | Impact of a program of adapted physical activity on the morphological, physiological, and biological parameters of sedentary hypertensive postmenopausal women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |